Dexrazoxane Reduces Heart Muscle Bleeding in Severe Heart Attack Patients

A recent clinical trial conducted by investigators at the Cardiovascular Imaging Research Center (CIRC) of Indiana University School of Medicine found that administering intravenous dexrazoxane before, during, and after percutaneous coronary intervention (PCI) significantly reduced intramyocardial hemorrhage (IMH) in adults suffering from ST‑segment elevation myocardial infarction (STEMI). The study enrolled patients who underwent coronary artery revascularization and measured the extent of bleeding within the heart muscle, a complication that can worsen outcomes after a severe heart attack.

Dexrazoxane, a chelating agent traditionally used to mitigate chemotherapy‑induced cardiotoxicity, was repurposed in this trial to protect myocardial tissue during the mechanical restoration of blood flow. By lowering the incidence of IMH, the drug may help preserve cardiac function and reduce the risk of heart failure in patients who experience a STEMI. The research team employed advanced cardiac imaging techniques to quantify hemorrhage and confirmed the therapeutic benefit across the cohort.

These findings suggest that dexrazoxane could become a valuable adjunct in acute coronary care, potentially improving recovery for patients undergoing PCI for STEMI. Further studies are warranted to confirm long‑term benefits and to establish optimal dosing protocols, but the trial provides a promising step toward reducing post‑infarction myocardial injury.